Victory Capital Management Inc. lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 8.9% during the fourth quarter, HoldingsChannel reports. The firm owned 26,252 shares of the medical technology company’s stock after acquiring an additional 2,138 shares during the period. Victory Capital Management Inc.’s holdings in Stryker were worth $4,065,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in SYK. Janus Henderson Group PLC boosted its position in shares of Stryker by 2,237.8% during the 2nd quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock worth $141,452,000 after purchasing an additional 975,656 shares in the last quarter. Colonial Trust Advisors lifted its position in Stryker by 56.1% in the 2nd quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock valued at $3,254,000 after acquiring an additional 8,426 shares in the last quarter. Peapack Gladstone Financial Corp lifted its position in Stryker by 8.9% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 55,516 shares of the medical technology company’s stock valued at $7,705,000 after acquiring an additional 4,546 shares in the last quarter. Cornerstone Capital Management Holdings LLC. lifted its position in Stryker by 0.3% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 53,572 shares of the medical technology company’s stock valued at $7,434,000 after acquiring an additional 135 shares in the last quarter. Finally, Green Square Capital LLC lifted its position in Stryker by 18.0% in the 2nd quarter. Green Square Capital LLC now owns 3,788 shares of the medical technology company’s stock valued at $527,000 after acquiring an additional 577 shares in the last quarter. 74.71% of the stock is currently owned by institutional investors.
Shares of Stryker Corporation (NYSE:SYK) opened at $159.87 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. The company has a market cap of $59,395.74, a PE ratio of 59.65, a price-to-earnings-growth ratio of 2.28 and a beta of 0.70. Stryker Corporation has a one year low of $124.89 and a one year high of $170.00.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. The firm had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the business posted $1.78 EPS. equities research analysts forecast that Stryker Corporation will post 7.12 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 annualized dividend and a yield of 1.18%. Stryker’s dividend payout ratio (DPR) is 70.15%.
In other Stryker news, Director Howard E. Cox, Jr. sold 7,400 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $164.09, for a total value of $1,214,266.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $160.53, for a total transaction of $479,021.52. Following the sale, the insider now owns 9,100 shares of the company’s stock, valued at approximately $1,460,823. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,840 shares of company stock valued at $2,749,989. Company insiders own 7.40% of the company’s stock.
Several brokerages recently weighed in on SYK. Oppenheimer set a $156.00 price target on shares of Stryker and gave the company a “hold” rating in a research report on Monday, October 30th. Canaccord Genuity raised their price target on shares of Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a research report on Friday, October 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research report on Wednesday, January 17th. Robert W. Baird raised shares of Stryker from a “neutral” rating to an “outperform” rating in a research report on Friday, November 24th. Finally, ValuEngine cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $162.50.
COPYRIGHT VIOLATION NOTICE: This article was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/02/18/stryker-corporation-syk-shares-bought-by-victory-capital-management-inc.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.